-
平臺編號：bio-68183
-
國際編號：ATCC CRL-2876
-
細(xì)胞信息： VCaP
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
VCaP
器官來源：前列腺
生長狀態(tài)：貼壁生長
年限：59 years
數(shù)量：大量
組織來源：vertebral metastasis
細(xì)胞形態(tài)：上皮樣
ATCC Number：CRL-2876?
相關(guān)疾?。耗[瘤
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞類型：上皮細(xì)胞
是否是腫瘤細(xì)胞：0
物種來源：人
規(guī)格：1ml Designations: VCaP
Depositors: ?KJ Pienta
Biosafety Level:2 [(cells produce the mouse xenotropic retrovirus Bxv-1) ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: prostate
Tissue: vertebral metastasis
Disease: cancer
Cell Type: epithelial
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: 1997
Applications:This line was established in 1997 from a vertebral bone metastasis from a patient with hormone refractory prostate cancer.
Tumorigenic:Yes
Antigen Expression:cytokeratin-18; Homo sapiens, expressed
p53 antigen; Homo sapiens, expressed
prostate specific antigen (PSA); Homo sapiens, expressed
prostatic acid phosphatase (PAP); Homo sapiens, expressed
Rb protein; Homo sapiens, expressed
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 11,12
D16S539: 9
D5S818: 12
D7S820: 9,12
THO1: 9.3
TPOX: 8,11
vWA: 18,19
Age: 59 years
Gender: male
Ethnicity: Caucasian
Comments:This line was established in 1997 from a vertebral bone metastasis from a patient with hormone refractory prostate cancer. It was passaged as xenografts in mice then cultured in vitro. It is androgen sensitive in vitro and in vivo.
Recently, it has been shown that VCaP prostate cancer cells produce the mouse xenotropic retrovirus Bxv-1, which was likely acquired by the cells during their xenotransplantation in mice.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
Interval: Subculture when the cell concentration reaches between 1 X 10(5) and 2 X 10(5) cells/sq. cm.
Subcultivation Ratio: 1:3 to 1:4
Preservation: Freeze medium: 95% growth medium; 5% DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: about 53 hours
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101
Cell culture tested DMSO:ATCC 4-X
Erythrosin B vital stain solution:ATCC 30-2404
Trypan Blue vital stain solution:ATCC 30-2402
References: 92253: Korenchuk S, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 15: 163-168, 2001. PubMed: 11317522
16173979: Knouf EC, et al. Multiple Integrated Copies and High-Level Production of the Human Retrovirus XMRV from 22Rv1 Prostate Carcinoma Cells. J. Virol. 83: 7353-7356, 2009. PubMed: 19403664
16173980: Sfanos KS, et al. Identification of replication competent murine gamma retroviruses in commonly used prostate cancer cell lines. PLoS One 6:e20874, 2011.
生長狀態(tài)：貼壁生長
年限：59 years
數(shù)量：大量
組織來源：vertebral metastasis
細(xì)胞形態(tài)：上皮樣
ATCC Number：CRL-2876?
相關(guān)疾?。耗[瘤
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞類型：上皮細(xì)胞
是否是腫瘤細(xì)胞：0
物種來源：人
規(guī)格：1ml Designations: VCaP
Depositors: ?KJ Pienta
Biosafety Level:2 [(cells produce the mouse xenotropic retrovirus Bxv-1) ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: prostate
Tissue: vertebral metastasis
Disease: cancer
Cell Type: epithelial
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: 1997
Applications:This line was established in 1997 from a vertebral bone metastasis from a patient with hormone refractory prostate cancer.
Tumorigenic:Yes
Antigen Expression:cytokeratin-18; Homo sapiens, expressed
p53 antigen; Homo sapiens, expressed
prostate specific antigen (PSA); Homo sapiens, expressed
prostatic acid phosphatase (PAP); Homo sapiens, expressed
Rb protein; Homo sapiens, expressed
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 11,12
D16S539: 9
D5S818: 12
D7S820: 9,12
THO1: 9.3
TPOX: 8,11
vWA: 18,19
Age: 59 years
Gender: male
Ethnicity: Caucasian
Comments:This line was established in 1997 from a vertebral bone metastasis from a patient with hormone refractory prostate cancer. It was passaged as xenografts in mice then cultured in vitro. It is androgen sensitive in vitro and in vivo.
Recently, it has been shown that VCaP prostate cancer cells produce the mouse xenotropic retrovirus Bxv-1, which was likely acquired by the cells during their xenotransplantation in mice.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
- Remove and discard culture medium.
- Briefly rinse the cell layer with Hank's Balanced Salt Solution or 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 1.0 to 2.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
-
Add appropriate aliquots of the cell suspension to new culture vessels.
An inoculum of 2 X 10(4) to 4 X 10(4) viable cells/sq. cm is recommended. - Incubate cultures at 37?C.
Interval: Subculture when the cell concentration reaches between 1 X 10(5) and 2 X 10(5) cells/sq. cm.
Subcultivation Ratio: 1:3 to 1:4
Preservation: Freeze medium: 95% growth medium; 5% DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: about 53 hours
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101
Cell culture tested DMSO:ATCC 4-X
Erythrosin B vital stain solution:ATCC 30-2404
Trypan Blue vital stain solution:ATCC 30-2402
References: 92253: Korenchuk S, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 15: 163-168, 2001. PubMed: 11317522
16173979: Knouf EC, et al. Multiple Integrated Copies and High-Level Production of the Human Retrovirus XMRV from 22Rv1 Prostate Carcinoma Cells. J. Virol. 83: 7353-7356, 2009. PubMed: 19403664
16173980: Sfanos KS, et al. Identification of replication competent murine gamma retroviruses in commonly used prostate cancer cell lines. PLoS One 6:e20874, 2011.
